Tilray Brands has spent the better part of two years doing the unglamorous work of getting its house in order - tightening its balance sheet, growing international medical cannabis sales, and inching toward sustainable profitability. The results are real. The problem is that none of it moves the stock in any meaningful way without a federal policy shift in the United States that remains, at best, uncertain in timing. For cannabis investors and B2B operators watching this space, that disconnect between improving operations and stubborn share price tells a clear story about where value actually lives right now.
The Fundamentals Are Real, But They Have a Ceiling
When Tilray reported results for its third fiscal quarter of 2026 - the period ending February 28 - the numbers were, by most measures, encouraging. Net revenue and gross profit grew 11% and 6% year over year, respectively. Its international cannabis segment, built largely on exports of medical-grade cannabis to European markets, posted 73% year-over-year sales growth. Adjusted EBITDA improved 19% to $10.7 million, and the net loss narrowed significantly to $25.2 million. Management reiterated full-year adjusted EBITDA guidance of $62 million to $72 million for the fiscal year ending June 30.
That's not nothing. In a sector where cash burn, balance sheet fragility, and regulatory whipsaw have erased companies entirely, demonstrating a credible path toward consistent profitability matters. But here's the catch: Tilray's market capitalization sits around $630 million - a valuation that can't be explained by its current earnings trajectory alone. The market is pricing in something larger. Specifically, access to the U.S. cannabis market at scale.
Without that access, Tilray is an international medical cannabis exporter with a beverage alcohol business and a Canadian adult-use operation - a mix with a finite growth ceiling. Operational improvements extend the runway. They don't change the destination.
Why U.S. Rescheduling Remains the Real Catalyst
Cannabis remains a Schedule I controlled substance under the U.S. Controlled Substances Act - classified alongside substances deemed to have a high potential for abuse and no accepted medical use. The proposed reclassification to Schedule III, which would acknowledge accepted medical use and a lower dependency profile, has been discussed in regulatory and political circles for some time. What it has not been is finalized.
For a company like Tilray, the significance of rescheduling - and ultimately, broader federal legalization - extends well beyond symbolic recognition. The U.S. adult-use and medical cannabis market is, by any measure, the largest regulated cannabis market in the world. Canadian licensed producers and multinational operators have been structurally locked out of it, unable to sell directly into a market they've been watching state-by-state operators build for years.
Rescheduling to Schedule III would not, on its own, open retail shelves to Canadian cannabis imports. Full federal legalization or a more permissive inter-state commerce framework would be required for that. But rescheduling matters for a different reason: it signals political will, creates legal and financial breathing room for ancillary businesses, and typically triggers a short-term rally across cannabis equities - including stocks like Tilray that have no current U.S. cannabis revenue to speak of.
To put it plainly: Tilray shares are trading partly on anticipation. And anticipation without a hard timeline is a thin foundation.
What This Means for Operators and Investors Watching the Sector
The Tilray situation reflects a broader strategic question that B2B operators and cannabis investors are working through right now. Not all cannabis stocks carry the same dependency on federal policy movement. Multi-state operators - companies that hold state-level licenses and operate dispensaries across several U.S. jurisdictions - have a fundamentally different risk and reward profile.
U.S.-based multi-state operators function under state-regulated frameworks. They are subject to 280E tax treatment under the federal tax code, which disallows standard business deductions for companies trafficking in Schedule I or II substances - a structural cost burden that rescheduling to Schedule III would directly relieve. That's a concrete, near-term financial catalyst tied to the same rescheduling conversation, not a speculative play on full legalization.
Beyond 280E relief, state-licensed operators are already generating revenue from licensed adult-use and medical sales, building brand equity inside compliant retail environments, and managing the day-to-day operational pressures of seed-to-sale tracking, METRC compliance, POS reconciliation, and wholesale supply chain management. Their upside from federal policy reform is additive - reduced tax burden, potential inter-state commerce, expanded access to banking and payments - rather than existential.
For Tilray, federal reform is closer to a prerequisite. That asymmetry matters when allocating attention or capital in this sector.
The Broader Regulatory Backdrop Still Shapes Everything
What's striking about the current moment in cannabis is how many intersecting policy threads are active simultaneously, yet how little has actually resolved. Rescheduling discussions have been ongoing. Banking access reform - most recently through the various iterations of SAFER Banking - has moved through committee stages without crossing a final legislative threshold. State-level markets continue to mature, with new jurisdictions moving through licensing, and others dealing with market saturation and pricing compression.
In that environment, companies that have built durable operations at the state level - managing compliant packaging, maintaining COA documentation, navigating excise tax structures, and surviving the compressed wholesale pricing that comes with market maturity - are doing something harder than most observers acknowledge. They are running regulated retail businesses under a tax and banking framework that would be unworkable in almost any other industry.
Tilray's improving fundamentals are a credit to its management. But the stock's real story hasn't changed. It remains a bet on U.S. federal policy. Until that policy moves - with real legislative language, timelines, and implementation rules - the gap between operational improvement and share price potential will stay exactly where it is.
